spacer
spacer

PDBsum entry 3n7o

Go to PDB code: 
protein ligands links
Hydrolase PDB id
3n7o

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
223 a.a. *
Ligands
NAG-NAG ×2
N7O
UNL ×2
Waters ×162
* Residue conservation analysis
PDB id:
3n7o
Name: Hydrolase
Title: X-ray structure of human chymase in complex with small molecule inhibitor.
Structure: Chymase. Chain: a. Synonym: alpha-chymase, mast cell protease i. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: chymase (16-245), cma1, cyh, cym. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
Resolution:
1.80Å     R-factor:   0.185     R-free:   0.210
Authors: M.C.Abad,J.Kervinen,C.Crysler,S.Bayoumy,J.Spurlino,I.Deckman, M.N.Greco,B.E.Maryanoff,L.Degaravilla
Key ref: J.Kervinen et al. (2010). Potency variation of small-molecule chymase inhibitors across species. Biochem Pharmacol, 80, 1033-1041. PubMed id: 20599788
Date:
27-May-10     Release date:   21-Jul-10    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P23946  (CMA1_HUMAN) -  Chymase from Homo sapiens
Seq:
Struc:
247 a.a.
223 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 2 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: E.C.3.4.21.39  - chymase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Preferential cleavage: Phe-|-Xaa > Tyr-|-Xaa > Trp-|-Xaa > Leu-|-Xaa.

 

 
Biochem Pharmacol 80:1033-1041 (2010)
PubMed id: 20599788  
 
 
Potency variation of small-molecule chymase inhibitors across species.
J.Kervinen, C.Crysler, S.Bayoumy, M.C.Abad, J.Spurlino, I.Deckman, M.N.Greco, B.E.Maryanoff, L.de Garavilla.
 
  ABSTRACT  
 
Chymases (EC 3.4.21.39) are mast cell serine proteinases that are variably expressed in different species and, in most cases, display either chymotryptic or elastolytic substrate specificity. Given that chymase inhibitors have emerged as potential therapeutic agents for treating various inflammatory, allergic, and cardiovascular disorders, it is important to understand interspecies differences of the enzymes as well as the behavior of inhibitors with them. We have expressed chymases from humans, macaques, dogs, sheep (MCP2 and MCP3), guinea pigs, and hamsters (HAM1 and HAM2) in baculovirus-infected insect cells. The enzymes were purified and characterized with kinetic constants by using chromogenic substrates. We evaluated in vitro the potency of five nonpeptide inhibitors, originally targeted against human chymase. The inhibitors exhibited remarkable cross-species variation of sensitivity, with the greatest potency observed against human and macaque chymases, with K(i) values ranging from approximately 0.4 to 72nM. Compounds were 10-fold to 300-fold less potent, and in some instances ineffective, against chymases from the other species. The X-ray structure of one of the potent phosphinate inhibitors, JNJ-18054478, complexed with human chymase was solved at 1.8A resolution to further understand the binding mode. Subtle variations in the residues in the active site that are already known to influence chymase substrate specificity can also strongly affect the compound potency. The results are discussed in the context of selecting a suitable animal model to study compounds ultimately targeted for human chymase.
 

 

spacer

spacer